# OnCo record reach-2 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/reach-2/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "reach-2", "NCT02435433" ;
  schema:name "REACH-2"@en ;
  schema:description "REACH-2 showed that the antibody ramucirumab helped people with liver cancer live longer after sorafenib, but only when a blood marker, alpha-fetoprotein, was high, making it the first liver cancer drug approved on a biomarker."@en ;
  schema:url <https://onco.cc/trials/reach-2/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02435433> ;
  onco:status "positive" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/hcc-advanced/>, <https://onco.cc/cancers/hcc/> ;
  onco:drugs <https://onco.cc/drugs/ramucirumab/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/> ;
  onco:people <https://onco.cc/people/andrew-zhu/> .